Aflac Swings to Profit on Investment Gains, Boosts Dividend

TL;DR

**Aflac's Q3 comeback is a green light for investors, as strong investment gains and a dividend hike signal robust financial health despite year-to-date headwinds.**

AI Summary

Aflac Incorporated reported a significant turnaround in net earnings for the three months ended September 30, 2025, reaching $1,639 million, a substantial increase from a net loss of $93 million in the same period of 2024. This improvement was primarily driven by a positive shift in net investment gains, which totaled $275 million in Q3 2025 compared to a loss of $1,408 million in Q3 2024. Total revenues for the quarter increased to $4,740 million from $2,949 million year-over-year. For the nine months ended September 30, 2025, net earnings decreased to $2,267 million from $3,541 million in 2024, largely due to net investment losses of $1,109 million compared to gains of $239 million in the prior year. Net earned premiums saw a modest increase, rising to $3,372 million in Q3 2025 from $3,328 million in Q3 2024, and to $10,223 million for the nine-month period from $10,109 million. The company also increased cash dividends per share to $0.58 in Q3 2025 from $0.50 in Q3 2024, reflecting confidence in its financial position. Total assets grew to $122,306 million as of September 30, 2025, from $117,566 million at December 31, 2024, with shareholders' equity increasing to $28,688 million from $26,098 million over the same period.

Why It Matters

Aflac's dramatic swing to profitability in Q3 2025, driven by a rebound in investment performance, signals improved financial health and potentially stronger returns for investors. The increase in cash dividends per share from $0.50 to $0.58 demonstrates management's confidence and commitment to shareholder value, which could attract income-focused investors. In a competitive insurance landscape, Aflac's ability to navigate market volatility and grow its premium base, albeit modestly, reinforces its market position. This performance could also impact employee morale and customer perception of the company's stability, especially given the challenging economic environment.

Risk Assessment

Risk Level: medium — While Aflac reported strong Q3 2025 net earnings of $1,639 million, the nine-month net earnings decreased significantly to $2,267 million from $3,541 million in 2024, primarily due to substantial net investment losses of $1,109 million for the nine-month period. This volatility in investment income, coupled with a $422 million allowance for credit losses on commercial mortgage and other loans as of September 30, 2025, up from $355 million at December 31, 2024, indicates ongoing exposure to market risks and potential credit deterioration.

Analyst Insight

Investors should closely monitor Aflac's investment portfolio performance and interest rate sensitivity, as these factors significantly impact net earnings. The increased dividend payout suggests a stable outlook, but the year-to-date decline in net earnings warrants caution. Consider Aflac for its dividend stability and potential for capital appreciation if investment gains continue, but be aware of the inherent volatility in its investment income.

Financial Highlights

debt To Equity

N/A

revenue

$4,740M

operating Margin

N/A

total Assets

$122,306M

total Debt

N/A

net Income

$1,639M

eps

$3.08

gross Margin

N/A

cash Position

N/A

revenue Growth

+60.7%

Revenue Breakdown

Key Numbers

• $1,639M — Net earnings for Q3 2025 (Significant turnaround from a net loss of $93 million in Q3 2024)
• $275M — Net investment gains for Q3 2025 (Reversed a net investment loss of $1,408 million in Q3 2024)
• $4,740M — Total revenues for Q3 2025 (Increased from $2,949 million in Q3 2024)
• $2,267M — Net earnings for nine months ended Sept 30, 2025 (Decreased from $3,541 million in the same period of 2024)
• $1,109M — Net investment losses for nine months ended Sept 30, 2025 (Contrasts with net investment gains of $239 million in the same period of 2024)
• $0.58 — Cash dividends per share for Q3 2025 (Increased from $0.50 per share in Q3 2024)
• $122,306M — Total assets as of Sept 30, 2025 (Increased from $117,566 million at December 31, 2024)
• $28,688M — Total shareholders' equity as of Sept 30, 2025 (Increased from $26,098 million at December 31, 2024)
• $422M — Allowance for credit losses on commercial mortgage and other loans as of Sept 30, 2025 (Increased from $355 million at December 31, 2024)
• 524,113,917 — Common shares outstanding as of Oct 27, 2025 (Reflects the current share count)

Key Players & Entities

• Aflac Incorporated (company) — Parent Company and registrant
• Aflac Life Insurance Japan Ltd. (ALIJ) (company) — Subsidiary operating in Japan
• American Family Life Assurance Company of Columbus (Aflac) (company) — Subsidiary operating in the U.S.
• American Family Life Assurance Company of New York (Aflac New York) (company) — Wholly owned subsidiary of Aflac
• Continental American Insurance Company (CAIC) (company) — Subsidiary marketing group products in the U.S.
• Tier One Insurance Company (TOIC) (company) — Subsidiary marketing consumer markets products in the U.S.
• Aflac Benefits Solutions, Inc. (ABS) (company) — Subsidiary administering dental and vision products in the U.S.
• New York Stock Exchange (regulator) — Exchange where Aflac Common Stock is registered
• Financial Accounting Standards Board (FASB) (regulator) — Establishes U.S. GAAP
• Aflac Re Bermuda Ltd. (Aflac Re) (company) — Involved in reinsurance activities

FAQ

Risk Factors

• Investment Portfolio Volatility [high — market]: The company experienced a significant swing in net investment gains/losses, with a $275 million gain in Q3 2025 compared to a $1,408 million loss in Q3 2024. For the nine-month period, net investment losses were $1,109 million versus gains of $239 million in the prior year. This volatility in investment performance directly impacts net earnings.
• Insurance Regulatory Environment [medium — regulatory]: Aflac operates in the insurance industry, which is subject to extensive regulation in the U.S. and Japan. Changes in regulations related to solvency, product offerings, or consumer protection could impact operations and profitability.
• Interest Rate Sensitivity [medium — financial]: The company's financial results are sensitive to changes in interest rates, as evidenced by the large impact of 'Effect of changes in discount rate assumptions' on other comprehensive income ($1,566M in Q3 2025 vs. -$1,889M in Q3 2024). Fluctuations in interest rates can affect investment income and the valuation of liabilities.
• Operational Expenses [medium — operational]: Total acquisition and operating expenses increased to $1,310 million in Q3 2025 from $1,262 million in Q3 2024. While revenue also grew, managing these expenses is crucial for maintaining profitability, especially in the face of potential economic headwinds.
• Credit Risk [medium — financial]: The allowance for credit losses on commercial mortgage and other loans increased to $422 million as of September 30, 2025, from $355 million at December 31, 2024. This indicates a potential increase in perceived credit risk within the loan portfolio.

Industry Context

Aflac operates in the supplemental health and life insurance sector, primarily in the U.S. and Japan. This industry is characterized by stable demand for its products, but faces challenges from evolving healthcare landscapes, interest rate sensitivity, and increasing regulatory scrutiny. Competition comes from both large, diversified insurers and specialized providers.

Regulatory Implications

The insurance industry is heavily regulated, with Aflac subject to oversight in both its operating jurisdictions. Changes in accounting standards, capital requirements, or consumer protection laws could necessitate adjustments to business practices and impact financial reporting.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]
4. [object Object]

Key Dates

• 2025-09-30: End of Q3 2025 — Reported significant turnaround in net earnings driven by investment gains, with total revenues increasing substantially year-over-year.
• 2024-09-30: End of Q3 2024 — Reported a net loss, heavily impacted by substantial net investment losses.
• 2025-12-31: End of Fiscal Year 2024 — Total assets stood at $117,566 million and shareholders' equity at $26,098 million.
• 2025-09-30: As of Q3 2025 — Total assets grew to $122,306 million and shareholders' equity to $28,688 million.

Glossary

Net earned premiums

The portion of insurance premiums that an insurance company has earned over a specific period. It represents revenue from insurance policies. (A core revenue driver for Aflac's insurance business.)

Net investment gains (losses)

The profit or loss realized from the sale or disposition of investments, or unrealized changes in the fair value of certain investments. (A significant factor in Aflac's quarterly and year-to-date earnings, showing high volatility.)

Reserve remeasurement (gains) losses

Adjustments made to the estimated future obligations (reserves) for claims that have been incurred but not yet paid. These adjustments can result in gains or losses. (Impacts the reported profitability of the insurance operations.)

Deferred policy acquisition costs (DAC)

Costs incurred in acquiring new insurance policies that are capitalized and amortized over the expected life of the policies. (Represents a significant operating expense that is recognized over time.)

Other comprehensive income (loss)

Includes unrealized gains and losses on investments, foreign currency translation adjustments, and other items that are not included in net earnings but affect shareholders' equity. (Shows the impact of market fluctuations and other economic factors on the company's overall financial position beyond net earnings.)

Year-Over-Year Comparison

Compared to the prior year's third quarter, Aflac has demonstrated a remarkable turnaround, shifting from a net loss of $93 million to a net earning of $1,639 million. This was primarily driven by a substantial positive swing in net investment gains, which reversed a significant loss from the previous year. Total revenues also saw a considerable increase, up by over 60% year-over-year. However, for the nine-month period, net earnings have decreased due to a negative shift in investment performance, despite modest growth in net earned premiums.

Filing Documents

• afl-20250930.htm (10-Q) — 6892KB
• afl093025ex311.htm (EX-31.1) — 11KB
• afl093025ex312.htm (EX-31.2) — 11KB
• afl093025ex32.htm (EX-32) — 9KB
• afl-20250930_g1.jpg (GRAPHIC) — 17KB
• 0001628280-25-049279.txt ( ) — 34460KB
• afl-20250930.xsd (EX-101.SCH) — 108KB
• afl-20250930_cal.xml (EX-101.CAL) — 108KB
• afl-20250930_def.xml (EX-101.DEF) — 932KB
• afl-20250930_lab.xml (EX-101.LAB) — 1347KB
• afl-20250930_pre.xml (EX-101.PRE) — 1165KB
• afl-20250930_htm.xml (XML) — 9678KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION: Page

Financial Statements (Unaudited)

Item 1. Financial Statements (Unaudited) Consolidated Statements of Earnings Three Months Ended September 30, 2025 and 2024 Nine Months Ended September 30, 2025 and 2024 1 Consolidated Statements of Comprehensive Income (Loss) Three Months Ended September 30, 2025 and 2024 Nine Months Ended September 30, 2025 and 2024 2 Consolidated Balance Sheets September 30, 2025, and December 31, 2024 3 Consolidated Statements of Shareholders' Equity Three Months Ended March 31, 2025 and 2024 Three Months Ended June 30, 2025 and 2024 Three Months Ended September 30, 2025 and 2024 4 Consolidated Statements of Cash Flows Nine Months Ended September 30, 2025 and 2024 8 Notes to the Consolidated Financial Statements 9

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 79

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 118

Controls and Procedures

Item 4. Controls and Procedures 118

OTHER INFORMATION

PART II. OTHER INFORMATION:

Risk Factors

Item 1A. Risk Factors 119

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 119

Other Information

Item 5. Other Information 119

Exhibits

Item 6. Exhibits 120 Glossary of Selected Terms 121 Items other than those listed above are omitted because they are not required or are not applicable.

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. Aflac Incorporated and Subsidiaries Consolidated Statements of Earnings Three Months Ended September 30, Nine Months Ended September 30, (In millions, except for share and per-share amounts - Unaudited) 2025 2024 2025 2024 Revenues: Net earned premiums, principally supplemental health insurance (1) $ 3,372 $ 3,328 $ 10,223 $ 10,109 Net investment income 1,067 1,006 3,103 3,100 Net investment gains (losses) 275 ( 1,408 ) ( 1,109 ) 239 Other income (loss) 26 23 81 76 Total revenues 4,740 2,949 12,298 13,524 Benefits and expenses: Benefits and claims, excluding reserve remeasurement 2,016 2,003 6,049 6,042 Reserve remeasurement (gains) losses ( 580 ) ( 408 ) ( 658 ) ( 515 ) Total benefits and claims, net 1,436 1,595 5,391 5,527 Acquisition and operating expenses: Amortization of deferred policy acquisition costs 218 214 655 638 Insurance commissions 254 251 745 751 Insurance and other expenses 781 747 2,387 2,179 Interest expense 57 50 159 147 Total acquisition and operating expenses 1,310 1,262 3,946 3,715 Total benefits and expenses 2,746 2,857 9,337 9,242 Earnings before income taxes 1,994 92 2,961 4,282 Income taxes 355 185 694 741 Net earnings $ 1,639 $ ( 93 ) $ 2,267 $ 3,541 Net earnings per share: Basic $ 3.09 $ ( .17 ) $ 4.22 $ 6.26 Diluted 3.08 ( .17 ) 4.21 6.23 Weighted-average outstanding common shares used in computing earnings per share (In thousands): Basic 530,050 557,899 537,095 565,757 Diluted 532,015 560,414 539,052 568,216 Cash dividends per share $ .58 $ .50 $ 1.74 $ 1.50 (1) Includes a gain (loss) of $( 55 ) and $( 75 ) for the three-month periods and $( 55 ) and $( 80 ) for the nine-month periods ended September 30, 2025 and 2024, respectively, related to remeasurement of the deferred profit liability for limited-payment contracts. See the accompanying Notes to the Consolidated Financial Statements. 1 Aflac Incorporated and Subsidiaries Consolidated Statements of Comprehensiv